CN119264073A - 激酶抑制剂及其用途 - Google Patents

激酶抑制剂及其用途 Download PDF

Info

Publication number
CN119264073A
CN119264073A CN202411240964.3A CN202411240964A CN119264073A CN 119264073 A CN119264073 A CN 119264073A CN 202411240964 A CN202411240964 A CN 202411240964A CN 119264073 A CN119264073 A CN 119264073A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
formula
haloalkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411240964.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·德·维森特·菲达尔戈
A·A·埃斯特拉达
J·A·冯
B·福克斯
C·M·弗朗西尼
C·R·H·海尔
C·胡
C·P·莱斯利
M·奥西波夫
E·塞拉
Z·K·斯威尼
A·图图姆卡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN119264073A publication Critical patent/CN119264073A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202411240964.3A 2017-05-17 2018-05-17 激酶抑制剂及其用途 Pending CN119264073A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US62/507,698 2017-05-17
US201862664895P 2018-04-30 2018-04-30
US62/664,895 2018-04-30
CN201880047293.5A CN110913858B (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途
PCT/US2018/033266 WO2018213632A1 (en) 2017-05-17 2018-05-17 Kinase inhibitors and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880047293.5A Division CN110913858B (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN119264073A true CN119264073A (zh) 2025-01-07

Family

ID=64274744

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880047293.5A Active CN110913858B (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途
CN202411240962.4A Pending CN119285572A (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途
CN202411240964.3A Pending CN119264073A (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201880047293.5A Active CN110913858B (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途
CN202411240962.4A Pending CN119285572A (zh) 2017-05-17 2018-05-17 激酶抑制剂及其用途

Country Status (21)

Country Link
US (3) US11203600B2 (enExample)
EP (1) EP3624797A4 (enExample)
JP (2) JP7064512B2 (enExample)
KR (1) KR102638151B1 (enExample)
CN (3) CN110913858B (enExample)
AU (1) AU2018269743B2 (enExample)
BR (1) BR112019023918A2 (enExample)
CA (1) CA3063934A1 (enExample)
CL (1) CL2019003263A1 (enExample)
CO (1) CO2019012957A2 (enExample)
CR (1) CR20190566A (enExample)
DO (1) DOP2019000290A (enExample)
EC (1) ECSP19089214A (enExample)
IL (1) IL270648B2 (enExample)
MX (2) MX2019013645A (enExample)
MY (1) MY200328A (enExample)
PE (2) PE20241932A1 (enExample)
PH (1) PH12019550235A1 (enExample)
SG (1) SG10201913927VA (enExample)
TW (1) TWI794232B (enExample)
WO (1) WO2018213632A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072019A1 (en) * 2018-10-19 2022-03-10 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
BR112023016539A2 (pt) * 2021-02-19 2023-11-14 Kalvista Pharmaceuticals Ltd Inibidores do fator xiia
WO2022231928A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use
EP4329765A4 (en) * 2021-04-27 2025-06-11 Merck Sharp & Dohme LLC Phenylazepines as RIPK1 inhibitors and methods of using them
JP2024544533A (ja) 2021-11-11 2024-12-03 ジェンザイム・コーポレーション Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用
TW202417453A (zh) * 2022-07-25 2024-05-01 美商戴納立製藥公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式
US20240100065A1 (en) * 2022-08-23 2024-03-28 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases
TW202444357A (zh) * 2023-01-23 2024-11-16 美商健臻公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物
TW202515552A (zh) * 2023-06-27 2025-04-16 美商健臻公司 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法
CN120365288A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物
CN120365287A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
EP1329450A4 (en) 2000-09-27 2005-08-31 Ajinomoto Kk BENZODIAZEPINE DERIVATIVE
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
CN104059068B (zh) 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
AU2016215432B2 (en) 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3307739B1 (en) * 2015-06-15 2020-10-07 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators

Also Published As

Publication number Publication date
AU2018269743B2 (en) 2024-01-11
US11203600B2 (en) 2021-12-21
BR112019023918A2 (pt) 2020-06-02
US20220041620A1 (en) 2022-02-10
CO2019012957A2 (es) 2020-05-29
TW201900618A (zh) 2019-01-01
JP7241825B2 (ja) 2023-03-17
JP7064512B2 (ja) 2022-05-10
MY200328A (en) 2023-12-20
KR102638151B1 (ko) 2024-02-16
EP3624797A1 (en) 2020-03-25
MX2019013645A (es) 2020-09-17
WO2018213632A1 (en) 2018-11-22
DOP2019000290A (es) 2020-03-15
ECSP19089214A (es) 2020-05-29
IL270648A (enExample) 2020-01-30
CN119285572A (zh) 2025-01-10
JP2020520924A (ja) 2020-07-16
US20250011338A1 (en) 2025-01-09
PE20200729A1 (es) 2020-07-23
IL270648B2 (en) 2024-03-01
CN110913858B (zh) 2024-09-24
TWI794232B (zh) 2023-03-01
CA3063934A1 (en) 2018-11-22
CR20190566A (es) 2020-06-14
EP3624797A4 (en) 2021-07-21
PE20241932A1 (es) 2024-09-24
US12129263B2 (en) 2024-10-29
JP2021193116A (ja) 2021-12-23
CN110913858A (zh) 2020-03-24
SG10201913927VA (en) 2020-03-30
IL270648B1 (en) 2023-11-01
PH12019550235A1 (en) 2020-07-20
KR20200006125A (ko) 2020-01-17
AU2018269743A1 (en) 2020-01-16
US20200087319A1 (en) 2020-03-19
MX2022010755A (es) 2022-09-23
CL2019003263A1 (es) 2020-04-17

Similar Documents

Publication Publication Date Title
JP7241825B2 (ja) キナーゼ阻害剤およびその使用
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
TWI436769B (zh) 類Ｐｏｌｏ激酶抑制劑
TWI378101B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
AU2016280137B2 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
IL265159A (en) Compounds and preparations as endosomal toll-like receptor inhibitors
ES2761903T3 (es) Derivados de carbazol
JP2021504380A (ja) Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
KR20170129192A (ko) Tnf의 억제제로서 유용한 헤테로시클릭 화합물
EP3625234B1 (en) Hexahydropyrazolo [1,2-a] diazepinones and related heterocycles as inhibitors of rip-1 kinase
JP2023062064A (ja) 軟骨形成を誘導するための化合物及び組成物
KR20250174938A (ko) 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 티아졸로피리딘 유도체
HK1238642A1 (en) Carbazole derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination